Anti-TGFBR3L monoclonal antibody

Pre-made anti-TGFBR3L monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to TGFBR3L/TGFBR3L products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1911-Ab-1/ GM-Tg-hg-IP1911-Ab-2Anti-Human TGFBR3L monoclonal antibodyHuman
GM-Tg-rg-IP1911-Ab-1/ GM-Tg-rg-IP1911-Ab-2Anti-Rat TGFBR3L monoclonal antibodyRat
GM-Tg-mg-IP1911-Ab-1/ GM-Tg-mg-IP1911-Ab-2Anti-Mouse TGFBR3L monoclonal antibodyMouse
GM-Tg-cynog-IP1911-Ab-1/ GM-Tg-cynog-IP1911-Ab-2Anti-Cynomolgus/ Rhesus macaque TGFBR3L monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1911-Ab-1/ GM-Tg-felg-IP1911-Ab-2Anti-Feline TGFBR3L monoclonal antibodyFeline
GM-Tg-cang-IP1911-Ab-1/ GM-Tg-cang-IP1911-Ab-2Anti-Canine TGFBR3L monoclonal antibodyCanine
GM-Tg-bovg-IP1911-Ab-1/ GM-Tg-bovg-IP1911-Ab-2Anti-Bovine TGFBR3L monoclonal antibodyBovine
GM-Tg-equg-IP1911-Ab-1/ GM-Tg-equg-IP1911-Ab-2Anti-Equine TGFBR3L monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1911-Ab-1/ GM-Tg-hg-IP1911-Ab-2; GM-Tg-rg-IP1911-Ab-1/ GM-Tg-rg-IP1911-Ab-2;
GM-Tg-mg-IP1911-Ab-1/ GM-Tg-mg-IP1911-Ab-2; GM-Tg-cynog-IP1911-Ab-1/ GM-Tg-cynog-IP1911-Ab-2;
GM-Tg-felg-IP1911-Ab-1/ GM-Tg-felg-IP1911-Ab-2; GM-Tg-cang-IP1911-Ab-1/ GM-Tg-cang-IP1911-Ab-2;
GM-Tg-bovg-IP1911-Ab-1/ GM-Tg-bovg-IP1911-Ab-2; GM-Tg-equg-IP1911-Ab-1/ GM-Tg-equg-IP1911-Ab-2
Products NameAnti-TGFBR3L monoclonal antibody
Formatmab
Target NameTGFBR3L
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-TGFBR3L monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1911-Ag-1Recombinant multi-species TGR3L/ TGFBR3L/ TGFR-3L protein


    Target information

    Target IDGM-IP1911
    Target NameTGFBR3L
    Gene ID100507588,100044509,688681,100428514,111091385,101100448,787301,111774203
    Gene Symbol and SynonymsGEMP,Gm14378,TGFBR3L,TGFR-3L
    Uniprot AccessionH3BV60
    Uniprot Entry NameTGR3L_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000260001
    Target ClassificationN/A

    The target: TGFBR3L, gene name: TGFBR3L, also named as TGFR-3L. Predicted to enable glycosaminoglycan binding activity; transforming growth factor beta-activated receptor activity; and type II transforming growth factor beta receptor binding activity. Predicted to contribute to transforming growth factor beta binding activity. Predicted to be involved in several processes, including blood vessel morphogenesis; regulation of transforming growth factor beta receptor signaling pathway; and transforming growth factor beta receptor signaling pathway. Predicted to be integral component of membrane. Predicted to be active in cell surface and extracellular space. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.